Advertisement

Ads Placeholder
Loading...

Genmab A/S

GMABNASDAQ
Healthcare
Biotechnology
$27.50
$0.28(1.03%)
U.S. Market opens in 27h 44m

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap16.9B
P/E Ratio6.15
EPS (TTM)$1.54
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$22.39
3 Months$33.87
1 Year Target$34.52

GMAB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GMAB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 52.61, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.52.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 6.15 and a market capitalization of 16.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.03%
5-Day Change
5.12%
1-Month Change
-0.58%
3-Month Change
-13.58%
6-Month Change
-18.06%
Year-to-Date (YTD) Change
-13.58%
1-Year Change
42.93%
3-Year Change
-26.78%
5-Year Change
-17.84%
All-Time (Max) Change
629.44%

Contact Information

45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

26,380 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions